Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $29.75, but opened at $31.30. Ascentage Pharma Group International shares last traded at $31.62, with a volume of 6,835 shares traded.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. started coverage on Ascentage Pharma Group International in a research report on Thursday, March 27th. They issued an "overweight" rating for the company.
Read Our Latest Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Price Performance
The stock has a 50-day simple moving average of $24.03.
Hedge Funds Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new position in Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International at the end of the most recent reporting period.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Further Reading
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
